SARASOTA, Fla., Dec. 1, 2021 /PRNewswire/ -- INVO Bioscience,
Inc. (NASDAQ: INVO), a medical device company focused on
commercializing the world's only in vivo culture system (IVC),
INVOcell®, today announced the Company has received
approval by Medical Devices Control Division for FDA Thailand to
import and commercialize INVOcell in Thailand. In April
2021, INVO Bioscience entered an exclusive distribution
agreement with IVF Envimed Company Ltd. to distribute the INVOcell
system within Thailand.
Established in 1993, IVF Envimed Company Ltd. has established a
wide network of clinics and hospitals across Thailand primarily focused on fertility
solutions. IVF Envimed is a member of the 'Thai Society of
Reproductive Medicine' which organizes congresses and educational
programs where IVF Envimed participates.
In November 2021, INVO Bioscience
started to train physicians and embryologists from both private and
government hospitals. In early 2022, INVO Bioscience and IVF
Envimed will organize several 'in person' trainings in Bangkok with key fertility experts to
supplement currently ongoing online trainings. INVO Bioscience is
also planning to conduct a locally-based evaluation study to have
localized data, a key element for both physicians and patients.
"Following months of efforts and interactions with the
governmental authorities in Thailand, we are thrilled to have received
approval by FDA Thailand to commence commercialization of the
INVOcell solution within Thailand," commented, Steve Shum, CEO of INVO Bioscience. "Over the
past number of months, we have been working closely with our
partners at IVF Envimed to educate key opinion leaders within the
country, including the recent training of several physicians and
embryologists that should allow us to begin scaling up our
commercialization efforts within the country. Further, we
have identified physicians to help us with localized data
collection on initial patients to assist in our longer term
marketing efforts within the country. We look forward to working
with Envimed and supporting their efforts to deliver the INVOcell
solution in Thailand help address
the underserved patient market in need of advanced reproductive
treatment."
About INVOcell
The INVOcell procedure is the first in-vivo culture (IVC) system
in the world used for the incubation of eggs and sperm during
fertilization and early embryo development within the body, as an
alternative to conventional In Vitro Fertilization (IVF) and
Intrauterine Insemination (IUI). Through its in vivo approach,
INVOcell offers patients a more natural and intimate experience
with comparable results at a lower cost.
About INVO Bioscience
We are a medical device company focused on creating simplified,
affordable treatments for patients diagnosed with infertility. Our
solution, the INVO® Procedure, is a revolutionary in
vivo method of vaginal incubation that offers patients a more
natural and intimate experience. Our lead product, the
INVOcell®, is a patented medical device used in
infertility treatment and is considered an Assisted Reproductive
Technology (ART). The INVOcell® is the first
Intravaginal Culture (IVC) system in the world used for the natural
in vivo incubation of eggs and sperm during fertilization and early
embryo development, as an alternative to traditional In Vitro
Fertilization (IVF) and Intrauterine Insemination (IUI). Our
mission is to increase access to care and expand fertility
treatment across the globe with a goal to lower the cost of care
and increase the availability of care. For more information, please
visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-obtains-regulatory-approval-to-commercialize-invocell-in-thailand-301434704.html
SOURCE INVO Bioscience, Inc.